Atripla three times weekly maintains HIV viral suppression for 24 weeks
Less frequent CD4 and viral load monitoring safe for people doing well on ART
Big increases in proportion of HIV-positive people in US treated with ART and with viral suppression
Sub-type C infection does not increase the risk of virologic failure when people are taking tenofovir-containing first-line ART
Very high levels of drug resistance seen in people experiencing first-line antiretroviral therapy failure in Kenya
ART has averted over 850,000 HIV-related opportunistic infections in low and middle income countries
Starting HIV therapy associated with improvements in liver function, especially when viral load is suppressed
START study shows that people starting HIV treatment earlier have better quality of life
Life expectancy in HIV-positive people in the US still lags 13 years behind HIV-negative people
